RDHL Latest Press Releases

-- November 2, 2026 --

Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate PRNewswire 7:00 AM

-- October 19, 2026 --

$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma PRNewswire 8:01 AM

-- October 1, 2026 --

Small Caps Test Their 200-Day Line as Yields Grind Higher and Earnings Season Stirs Globe Newswire 6:24 PM

-- September 30, 2026 --

RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results PRNewswire 4:05 PM

-- September 1, 2026 --

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota and Clenpiq PRNewswire 7:01 AM

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota and Clenpiq Globe Newswire 7:00 AM

-- August 31, 2026 --

RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities PRNewswire 7:00 AM

-- July 28, 2026 --

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development PRNewswire 7:00 AM

-- June 22, 2026 --

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement PRNewswire 4:10 PM

-- June 18, 2026 --

RedHill Biopharma Announces Up To $19.4 Million Private Placement PRNewswire 8:00 AM

Market Data Delayed 15 Minutes